AIM: To explain the role of Monocyte chemotactic protein-1 (MCP-1) and soluble adhesion molecules in chronic hepatitis C during the treatment of interferon alpha (IFNalpha) 2 b and ribavirin (RBV). METHODS: Concentrations of MCP-1, soluble adhesion molecules intercellular adhesion molecule-1 (sICAM-1), sP-selectin, interleukin (IL) 6, and IL10 in serum were estimated in the group of 40 patients with chronic hepatitis C treated with IFNalpha2 b and RBV in 0, 16, 32, 48 wk of the therapy. RESULTS: In chronic hepatitis C, before and during the treatment, the serum levels of MCP-1 and sP-selectin in responders were similar to those of healthy subjects. In non-responders (NR), MCP-1 increased in the course of IFNalpha+RBV treatment, differences were statistically significant as compared to responders. MCP-1 correlated statistically with the activity of periportal inflammation (r = 0.35, P<0.05) but not with staging of liver fibrosis. sICAM-1 positively correlated with inflammatory activity and fibrosis in NR. sP-selectin did not correlate with histological findings in the liver. The MCP-1 correlated with the soluble form of sP-selectin concentrations (r = 6, P<0.001) and with IL-10 level in NR (r = 0.4, P<0.05). There was no correlation observed between the concentration of MCP-1 and sICAM-1, IL-6 during the treatment. CONCLUSION: MCP-1 concentration may be a prognostic marker of the efficacy of IFN+RBV therapy in patients with chronic hepatitis C.
AIM: To explain the role of Monocyte chemotactic protein-1 (MCP-1) and soluble adhesion molecules in chronic hepatitis C during the treatment of interferon alpha (IFNalpha) 2 b and ribavirin (RBV). METHODS: Concentrations of MCP-1, soluble adhesion molecules intercellular adhesion molecule-1 (sICAM-1), sP-selectin, interleukin (IL) 6, and IL10 in serum were estimated in the group of 40 patients with chronic hepatitis C treated with IFNalpha2 b and RBV in 0, 16, 32, 48 wk of the therapy. RESULTS: In chronic hepatitis C, before and during the treatment, the serum levels of MCP-1 and sP-selectin in responders were similar to those of healthy subjects. In non-responders (NR), MCP-1 increased in the course of IFNalpha+RBV treatment, differences were statistically significant as compared to responders. MCP-1 correlated statistically with the activity of periportal inflammation (r = 0.35, P<0.05) but not with staging of liver fibrosis. sICAM-1 positively correlated with inflammatory activity and fibrosis in NR. sP-selectin did not correlate with histological findings in the liver. The MCP-1 correlated with the soluble form of sP-selectin concentrations (r = 6, P<0.001) and with IL-10 level in NR (r = 0.4, P<0.05). There was no correlation observed between the concentration of MCP-1 and sICAM-1, IL-6 during the treatment. CONCLUSION:MCP-1 concentration may be a prognostic marker of the efficacy of IFN+RBV therapy in patients with chronic hepatitis C.
Authors: F Marra; R G Romanelli; C Giannini; P Failli; S Pastacaldi; M C Arrighi; M Pinzani; G Laffi; P Montalto; P Gentilini Journal: Hepatology Date: 1999-01 Impact factor: 17.425
Authors: G Taliani; M C Badolato; A Bozza; G Poliandri; F Duca; C Pasquazzi; R Lecce; R Bruni; C De Bac Journal: Arch Virol Date: 1997 Impact factor: 2.574
Authors: F Marra; R DeFranco; C Grappone; S Milani; S Pastacaldi; M Pinzani; R G Romanelli; G Laffi; P Gentilini Journal: Am J Pathol Date: 1998-02 Impact factor: 4.307
Authors: Marcus Mühlbauer; Anja K Bosserhoff; Arndt Hartmann; Wolfgang E Thasler; Thomas S Weiss; Hans Herfarth; Guntram Lock; Jürgen Schölmerich; Claus Hellerbrand Journal: Gastroenterology Date: 2003-10 Impact factor: 22.682
Authors: Lauren E Kushner; Aaron M Wendelboe; Laura C Lazzeroni; Aarthi Chary; Mark A Winters; Anu Osinusi; Shyam Kottilil; Michael A Polis; Mark Holodniy Journal: PLoS One Date: 2013-04-04 Impact factor: 3.240
Authors: Nora E I El-Bassiouni; Ola M Mahmoud; Eman G El Ahwani; Raafat A Ibrahim; Azza E I El Bassiouny Journal: Mediterr J Hematol Infect Dis Date: 2013-09-02 Impact factor: 2.576
Authors: Paul Ravi Waldron; Ilana Belitskaya-Lévy; Aarthi Chary; Johann Won; Mark Winters; Alexander Monto; James Ryan; Laura C Lazzeroni; Mark Holodniy Journal: J Immunol Res Date: 2016-06-02 Impact factor: 4.818
Authors: Mihail Virgil Boldeanu; Isabela Siloşi; Andreea Lili Bărbulescu; Raluca Elena Sandu; Cristiana Geormăneanu; Vlad Pădureanu; Mircea Vasile Popescu-Drigă; Ioan Sabin Poenariu; Cristian Adrian Siloşi; Anca Marilena Ungureanu; Anda Lorena Dijmărescu; Lidia Boldeanu Journal: Rom J Morphol Embryol Date: 2020 Impact factor: 1.033